SR-BI. ML278 is a plasma-stable, noncytotoxic probe that exhibits moderate metabolic stability, thus displaying improved properties for in vitro and in vivo studies. Strikingly, ML278 and previously described inhibitors of lipid transport share the property of increasing the binding of HDL to SR-BI, rather than blocking it, suggesting there may be similarities in their mechanisms of action.
通过高通量筛选的美国国立卫生研究院分子图书馆小分子知识库(NIH MLSMR),鉴定了由
吲哚基-
噻唑类有效的一类由清除剂受体B类I型介导的细胞脂质摄取
抑制剂(SR-BI) ),以测定从HDL颗粒摄取荧光脂质DiI的方法。这类化合物由M
L278(17 – 11)代表,它很有效(平均IC 50= 6 nM)和通过SR-BI摄取脂质的可逆
抑制剂。M
L278是一种血浆稳定的,无细胞毒性的探针,具有中等的代谢稳定性,因此在体外和体内研究中显示出改进的特性。令人惊讶的是,M
L278和先前描述的脂质转运
抑制剂具有增加HDL与SR-BI结合而不是阻断它的特性,表明它们的作用机理可能相似。